ReposiTrak reported Q3 FY2026 results yesterday after the bell — and the print landed squarely in the middle of a story that had been building for weeks around short positioning, a CEO selling programme, and a stock price that had recovered sharply from its February lows.
Short sellers have been quietly adding pressure through the month. Short interest climbed nearly 9% over the trailing 30 days to reach almost 8.8% of the free float, with days to cover running close to seven sessions on official FINRA data. The ORTEX short score of 72.9 — placing the stock in roughly the 96th percentile of the universe by short-side intensity — confirms this is not casual hedging. The borrow market, however, remains accessible. Availability is well above 200% of short interest, meaning there is ample lending supply relative to the position, and cost to borrow has actually eased over the past month to under 1.5%. That combination — rising short interest alongside loose borrow — points to conviction shorts, not a squeeze-prone setup.
Options positioning tells a calmer story than the short side. The put/call ratio is running at 0.32, just below its 20-day average and barely a fraction of a standard deviation from the norm. Call-side activity has been dominant throughout April and into May, making options traders the more constructive voice heading into the print. That is notable against a short score sitting near the high end of the range.
The CEO's own behaviour adds a layer of complexity. Randall Fields — Founder, Chairman and President/CEO — sold shares on ten separate occasions between late February and late March, accumulating roughly $310,000 in proceeds across 35,000 shares at prices in the $8.00–$8.75 range. Those sales came before the stock's 19% one-month rally to $9.10. Fields still controls approximately 21.5% of shares outstanding, so the transactions were incremental rather than a structural exit — but the cadence of the selling is consistent and systematic, and it continued close to the quarter-end results that were subsequently released. The only analyst target on record is a $24 Buy initiated by Maxim Group in May 2024, a data point now more than two years old and not reliable as current Street consensus.
Yesterday's Q3 print itself beat on earnings — EPS of $0.11 against a $0.09 estimate — while sales of $5.88 million narrowly missed the $5.90 million consensus. That pattern echoes the prior quarter, when Q2 revenue grew year-on-year but the February result triggered a roughly 10.6% one-day decline and an 18.6% drop over five sessions. The Q3 print was a tighter miss. Whether the market treats a revenue shortfall — however slim — as a signal about the pace of new client wins or FSMA 204 traceability adoption is what the post-earnings price action will now reflect.
See the live data behind this article on ORTEX.
Open TRAK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
